Autopsy report · NCT02978651

Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness

“Strategic decision of Sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Bioprojet

Sponsor type

University, hospital or other

Conditions

Excessive Daytime Sleepiness; Obstructive Sleep Apnea

Interventions

Pitolisant (BF2.649); Placebo Oral Tablet

Participants

0

Sites

2

Countries

France

Trials that died the same way

• Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant
  “Strategic sponsor decision” (98% match in meaning)
• High-Risk Skin Cancers With Atezolizumab Plus NT-I7
  “Strategic decision by sponsor” (98% match in meaning)
• Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19
  “Sponsor's strategic decision” (98% match in meaning)
• Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis
  “Sponsor decision due to strategic considerations” (96% match in meaning)
• A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
  “Sponsor's strategic business decision” (94% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.